Ka-Man Venus Lai

USPTO Granted Patents = 54 (Patent Applications = 24)

CIPO Patents = 9 (Patent Applications = 11)

EPO Patents = 25 (Patent Applications = 34)

Average Co-Inventor Count = 5.1

ph-index = 9

Forward Citations = 292(Granted Patents)

Forward Citations (Not Self Cited) = 158(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Tarrytown, NY (US) (2013 - 2021)
San Francisco, CA (US) (2019 - 2022)
Seattle, WA (US) (2020 - 2024)

Company Filing History:

50 out of 1,345

Regeneron Pharmaceuticals, Inc.

patents

4 out of 49

Regeneran Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Humanized CD3 Complex

Antigen-Binding Proteins

Genetically Modified Mice

Targeted Genetic Modification

Nuclease-Mediated DNA Assembly

Neonatal Progeroid Syndrome

Rodent Models

C9ORF72 Locus

Stem Cell Modification

Prostate Cancer Models

miRNA-Regulated Differentiation

Promoter-Regulated Self-Deleting Cassette

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12419282 - Non-human animals expressing humanized CD3 complex (2025-09-23),

2. 12369570 - Humanized IL-15 animals (2025-07-29),

3. 12342801 - Methods for producing antigen-binding proteins against foreign antigens (2025-07-01),

4. 12089575 - Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins (2024-09-17),

5. 12065661 - Genetic modification of rats (2024-08-20),

6. 12037596 - Targeted modification of rat genome (2024-07-16),

7. 11937587 - Non-human animals expressing humanized CD3 complex (2024-03-26),

8. 11932859 - Nuclease-mediated DNA assembly (2024-03-19),

9. 11820997 - Methods and compositions for the targeted modification of a genome (2023-11-21),

10. 11730150 - Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy (2023-08-22),

11. 11697828 - Methods and compositions for targeted genetic modification using paired guide RNAs (2023-07-11),

12. 11684050 - Non-human animals having a humanized programmed cell death 1 gene (2023-06-27),

13. 11589562 - Mouse model of DITRA disease and uses thereof (2023-02-28),

14. 11547101 - Non-human animals having a disruption in a C9ORF72 locus (2023-01-10),

15. 11547100 - Method for screening gene expression in lincRNA-deficient mice or rats (2023-01-10),

Sure, I can help with that. Let's start with the article structure. Here's what we'll cover:

Title: The Innovative Work of Inventor Ka-Man Venus Lai

Introduction: Brief overview of Ka-Man Venus Lai and his contributions

Latest Patents: Description of his two latest patents

Career Highlights: Summary of his work at Regeneron Pharmaceuticals, Inc.

Collaborations: Mention of his coworkers David M. Valenzuela and David Frendewey

Conclusion: Wrap up his achievements and impact

Let's begin with the content for each section. Shall we proceed with the article?

This text is generated by artificial intelligence and may not be accurate.